Form 8-K - Current report:
SEC Accession No. 0001193125-25-183449
Filing Date
2025-08-19
Accepted
2025-08-19 16:25:28
Documents
14
Period of Report
2025-08-19
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d947561d8k.htm   iXBRL 8-K 51538
2 EX-99.1 d947561dex991.htm EX-99.1 8728
6 GRAPHIC g947561g0819224408296.jpg GRAPHIC 3115
  Complete submission text file 0001193125-25-183449.txt   184938

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA jagx-20250819.xsd EX-101.SCH 2876
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE jagx-20250819_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE jagx-20250819_pre.xml EX-101.PRE 11278
17 EXTRACTED XBRL INSTANCE DOCUMENT d947561d8k_htm.xml XML 3672
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36714 | Film No.: 251232135
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)